## EW: Edwards Lifesciences Corporatio - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.6% below STRENGTH zone (4.0-10.0%); PEG 4.78 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (47% of avg), momentum weakening (-2.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($81.45)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. First National Advisers LLC Buys 9,644 Shares of Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251130T101153 | Somewhat-Bullish | Relevance: 99%
- First National Advisers LLC has increased its stake in Edwards Lifesciences Corporation (EW) by 30.3%, acquiring an additional 9,644 shares to bring their total holdings to 41,484 shares valued at approximately $3.245 million. This comes after Edwards Lifesciences reported strong Q3 earnings, beating estimates and raising its FY2025 EPS guidance. The company maintains a "Moderate Buy" consensus rating from analysts, with a target price of $91.39, despite some insider selling.

**2. Edwards Lifesciences Corporation (NYSE:EW) Given Average Recommendation of "Moderate Buy" by Analysts**
- Source: MarketBeat | 20251130T063734 | Somewhat-Bullish | Relevance: 98%
- Edwards Lifesciences Corporation (NYSE:EW) has received an average "Moderate Buy" recommendation from analysts, with a consensus target price of $91.39. The company recently surpassed Q3 earnings and revenue expectations and provided positive FY2025 guidance. Notable insider selling occurred in November, while hedge funds and institutional investors hold a significant portion of the company's stock.

**3. Korea Investment CORP Has $36.33 Million Holdings in Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251130T115105 | Somewhat-Bullish | Relevance: 98%
- Korea Investment CORP reduced its stake in Edwards Lifesciences Corporation by 28.2% in Q2, bringing its total holdings to 464,573 shares valued at approximately $36.33 million. Other institutional investors like Vanguard Group Inc. and Geode Capital Management LLC also adjusted their positions. Edwards Lifesciences recently surpassed Q3 earnings expectations and received a "Moderate Buy" analyst rating with an average target price of $91.39.

**4. Laurel Wealth Advisors LLC Raises Position in Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251130T112125 | Somewhat-Bullish | Relevance: 98%
- Laurel Wealth Advisors LLC significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 7,721.7% during Q2, now holding 5,397 shares valued at $422,000. Edwards Lifesciences reported strong Q3 earnings, beating analyst estimates, and provided positive FY2025 guidance. Despite some insider selling, institutional ownership remains high, and analysts maintain a "Moderate Buy" rating with an average price target of $91.39.

**5. HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: Finviz | 20251130T152900 | Neutral | Relevance: 97%
- Halper Sadeh LLC, an investor rights law firm, is investigating potential breaches of fiduciary duties by officers and directors of Edwards Lifesciences Corporation (NYSE: EW). The firm encourages current long-term shareholders to contact them to discuss their legal rights, which may include seeking corporate governance reforms or financial incentives. Their participation could help improve company policies and enhance shareholder value.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Barclays | $103 | $99 | +4% |
| 2025-12-05 | Canaccord Genui | $89 | $84 | +6% |
| 2025-12-05 | Stifel | $100 | $95 | +5% |
| 2025-12-05 | UBS | $92 | $90 | +2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Barclays | main | Overweight |
| 2025-12-05 | Canaccord Genui | main | Hold |
| 2025-12-05 | Stifel | main | Buy |
| 2025-12-05 | UBS | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.06M) |
| Sells | 3 ($0.90M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 4.8x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 9 raises (avg +4%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 4.78 signals overvaluation risk, limited margin of safety. Forward P/E 29.7x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $49.3B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.78 |
| Forward P/E | 29.7 |
| Current P/E | 33.0 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.8% to -0.6% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.6pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. Volume at 47% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.60% (CS: 44) | Neutral |
| RSI_14 | 57.0 | Neutral |
| MACD Histogram | -0.17 | Bearish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 1.067x | Above |
| vs SMA200 | 1.114x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $85.27
- **Stop Loss:** $81.45 (4.5% risk)
- **Target:** $89.09 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 196
- **Position Value:** $16,712.92
- **Portfolio %:** 16.71%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*